A modified version of the adult 7-marker biosignature in which transthyretin was replaced by NCAM1, diagnosed TBM in children with AUC of 0.80 (95% CI, 0.67-0.92), sensitivity of 73.9% (95% CI, 51.6-89.8%) and specificity of 66.7% (95% CI, 44.7-84.4%), with the other six proteins in the signature (CRP, IFN-γ, IP-10, CFH, Apo-A1, and SAA) only achieving and AUC of 0.75 (95% CI, 0.61-0.90) when used in combination.
A total of 32.8% (22/67) patients with TBM developed DIH that was associated with worsening in GCS score (p=0.01), stage TBM (p=0.02), SIRS parameters (p=0.04), ESR (p=0.04) and CRP (p<0.01) compared with their baseline.